Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.52 |
| ▸ | JAK3 | P52333 | 3/20 | 0.51 |
| ▸ | JAK1 | P23458 | 2/20 | 0.51 |
| ▸ | JAK2 | O60674 | 2/20 | 0.51 |
| ▸ | TYK2 | P29597 | 2/20 | 0.51 |
| ▸ | CDK1 | P06493 | 5/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.49 |
| ▸ | CDK9 | P50750 | 4/20 | 0.49 |
| ▸ | KDR | P35968 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | PDE5A | O76074 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12781061 | 0.89 | JAK2 (0.48) | BACE1JAK3JAK1JAK2TYK2 | |
| SCHEMBL12781005 | 0.89 | BACE1 (0.59) | BACE1JAK3JAK1JAK2TYK2 | |
| SCHEMBL12781111 | 0.88 | CCNT1 (0.51) | BACE1JAK3JAK1JAK2TYK2 | |
| SCHEMBL13963596 | 0.79 | TNNI3K (0.42) | BACE1JAK3JAK1JAK2TYK2 | |
| SCHEMBL12780945 | 0.78 | JAK3 (0.51) | BACE1JAK3JAK1JAK2TYK2 | |
| SCHEMBL4044746 | 0.77 | FLT3 (0.67) | JAK3JAK1JAK2TYK2CDK1 | |
| SCHEMBL12780903 | 0.75 | FLT3 (0.67) | BACE1JAK2KDRAURKALCK | |
| SCHEMBL12781046 | 0.73 | JAK1 (0.51) | JAK3JAK1JAK2TYK2CDK1 | |
| SCHEMBL12781086 | 0.73 | CCNT1 (0.45) | CDK1CCNT1CCNB1CDK9CYP2D6 | |
| SCHEMBL12781028 | 0.71 | JAK2 (0.50) | BACE1JAK3JAK1JAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902239-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902239-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K5 | BACE1 3044/4885JAK3 134/4885JAK1 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.